143 related articles for article (PubMed ID: 37015029)
1. Determining the Efficacy of Pembrolizumab in Patients With Previously Treated Advanced Hepatocellular Carcinoma.
Lin TA; Das A; McCaw Z; Ludmir EB
J Clin Oncol; 2023 Jun; 41(16):3074-3075. PubMed ID: 37015029
[No Abstract] [Full Text] [Related]
2. Complete Response to the Combination of Pembrolizumab and Sorafenib for Metastatic Hepatocellular Carcinoma: A Case Report.
Chen SC; Chao Y; Yang MH
Am J Gastroenterol; 2017 Apr; 112(4):659-660. PubMed ID: 28381841
[No Abstract] [Full Text] [Related]
3. Pembrolizumab for metastatic hepatocellular carcinoma following live donor liver transplantation: The silver bullet?
Rammohan A; Reddy MS; Farouk M; Vargese J; Rela M
Hepatology; 2018 Mar; 67(3):1166-1168. PubMed ID: 29023959
[No Abstract] [Full Text] [Related]
4. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.
Zhu AX; Finn RS; Edeline J; Cattan S; Ogasawara S; Palmer D; Verslype C; Zagonel V; Fartoux L; Vogel A; Sarker D; Verset G; Chan SL; Knox J; Daniele B; Webber AL; Ebbinghaus SW; Ma J; Siegel AB; Cheng AL; Kudo M;
Lancet Oncol; 2018 Jul; 19(7):940-952. PubMed ID: 29875066
[TBL] [Abstract][Full Text] [Related]
5. Complete response to the combination of sintilimab and IBI305 for a patient with HBV-associated hepatocellular carcinoma with multiple lung metastasis.
Duan X; Zhang H; Zhou L; Jiang B; Mao X
Dig Liver Dis; 2020 Jul; 52(7):794-796. PubMed ID: 32386943
[No Abstract] [Full Text] [Related]
6. Acute liver failure caused by pembrolizumab in a patient with pulmonary metastatic liver cancer: A case report.
Wu Z; Lai L; Li M; Zhang L; Zhang W
Medicine (Baltimore); 2017 Dec; 96(51):e9431. PubMed ID: 29390572
[TBL] [Abstract][Full Text] [Related]
7. Pembrolizumab for second line treatment of advanced hepatocellular carcinoma-who would benefit?
Ladekarl M
Chin Clin Oncol; 2023 Apr; 12(2):10. PubMed ID: 36908273
[No Abstract] [Full Text] [Related]
8. Pembrolizumab: a potential game-changer in the treatment of advanced hepatocellular carcinoma.
Shek D; Ahlenstiel G
Chin Clin Oncol; 2023 Oct; 12(5):47. PubMed ID: 37691347
[No Abstract] [Full Text] [Related]
9. Phase 2 study of pembrolizumab and circulating biomarkers to predict anticancer response in advanced, unresectable hepatocellular carcinoma.
Feun LG; Li YY; Wu C; Wangpaichitr M; Jones PD; Richman SP; Madrazo B; Kwon D; Garcia-Buitrago M; Martin P; Hosein PJ; Savaraj N
Cancer; 2019 Oct; 125(20):3603-3614. PubMed ID: 31251403
[TBL] [Abstract][Full Text] [Related]
10. Atezolizumab plus bevacizumab for advanced, unresectable hepatocellular carcinoma.
Tsilimigras DI; Moris D
J BUON; 2021; 26(2):637. PubMed ID: 34077021
[No Abstract] [Full Text] [Related]
11. Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors.
Wong JSL; Kwok GGW; Tang V; Li BCW; Leung R; Chiu J; Ma KW; She WH; Tsang J; Lo CM; Cheung TT; Yau T
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33563773
[TBL] [Abstract][Full Text] [Related]
12. Quantification of Treatment Effect of Tislelizumab vs Sorafenib for Hepatocellular Carcinoma.
Sun R; Moraleda JM; Wei LJ
JAMA Oncol; 2024 May; 10(5):674. PubMed ID: 38483380
[No Abstract] [Full Text] [Related]
13. Quantification of Treatment Effect of Tislelizumab vs Sorafenib for Hepatocellular Carcinoma-Reply.
Qin S
JAMA Oncol; 2024 May; 10(5):674-675. PubMed ID: 38483395
[No Abstract] [Full Text] [Related]
14. Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial.
Finn RS; Ryoo BY; Merle P; Kudo M; Bouattour M; Lim HY; Breder V; Edeline J; Chao Y; Ogasawara S; Yau T; Garrido M; Chan SL; Knox J; Daniele B; Ebbinghaus SW; Chen E; Siegel AB; Zhu AX; Cheng AL;
J Clin Oncol; 2020 Jan; 38(3):193-202. PubMed ID: 31790344
[TBL] [Abstract][Full Text] [Related]
15. The clinical application of camrelizumab on advanced hepatocellular carcinoma.
Chen Z; Lu X; Koral K
Expert Rev Gastroenterol Hepatol; 2020 Nov; 14(11):1017-1024. PubMed ID: 32762583
[TBL] [Abstract][Full Text] [Related]
16. Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ).
Bang YJ; Golan T; Dahan L; Fu S; Moreno V; Park K; Geva R; De Braud F; Wainberg ZA; Reck M; Goff L; Laing N; Mi G; Oliveira JM; Wasserstrom H; Lin CC
Eur J Cancer; 2020 Sep; 137():272-284. PubMed ID: 32827847
[TBL] [Abstract][Full Text] [Related]
17. Successful Treatment of Therapy-related Acute Promyelocytic Leukemia with All-trans-retinoic acid Following Epirubicin for Hepatocellular Carcinoma and Docetaxel and Pembrolizumab Therapies for Lung Carcinoma: A Triple Malignancy Case.
Suzuki R; Kawai H; Furuya D; Akashi H; Ogawa Y; Kawada H; Ando K
Tokai J Exp Clin Med; 2020 Jul; 45(2):92-96. PubMed ID: 32602108
[TBL] [Abstract][Full Text] [Related]
18. Systemic Therapy for Hepatocellular Carcinoma: Advances and Hopes.
Zhang CH; Li M; Lin YP; Gao Q
Curr Gene Ther; 2020; 20(2):84-99. PubMed ID: 32600231
[TBL] [Abstract][Full Text] [Related]
19. Cabozantinib plus atezolizumab in advanced hepatocellular carcinoma and the role of adjuvant antiviral therapy.
Ji F; Nguyen MH
Lancet Oncol; 2022 Aug; 23(8):962-963. PubMed ID: 35798015
[No Abstract] [Full Text] [Related]
20. Sintilimab plus sorafenib: a novel regimen for hepatocellular carcinoma.
Liu X; Yi Y
Immunotherapy; 2021 Dec; 13(17):1387-1393. PubMed ID: 34665016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
